Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis
Version 2 2024-01-28, 05:05Version 2 2024-01-28, 05:05
Version 1 2023-06-13, 09:58Version 1 2023-06-13, 09:58
journal contribution
revised on 2024-01-28, 05:03 and posted on 2024-01-28, 05:05authored byShilpa Kuttikrishnan, Tariq Masoodi, Gulab Sher, Ajaz A. Bhat, Kalyani Patil, Tamam El-Elimat, Nicholas H. Oberlies, Cedric J. Pearce, Mohmmad Haris, Aamir Ahmad, Feras Q. Alali, Shahab Uddin
<p>Abnormal expression of Forkhead box protein M1 (FOXM1) and serine/threonine kinase Budding uninhibited by benzimidazoles 1 (BUB1B) contributes to the development and progression of several cancers, including chronic myelogenous leukemia (CML). However, the molecular mechanism of the FOXM1/BUB1B regulatory network and the role of Neosetophomone-B (NSP-B) in leukemia remains unclear. NSP-B, a meroterpenoid fungal secondary metabolite, possesses anticancer potential in human leukemic cells lines; however, the underlying mechanism has not been elucidated. The present study aimed to explore the role of NSP-B on FOXM1/BUB1B signaling and the underlying molecular mechanism of apoptosis induction in leukemic cells. We performed gene expression profiling of NSP-B-treated and untreated leukemic cells to search for differentially expressed genes (DEGs). Interestingly <em>BUB1B</em> was found to be significantly downregulated (logFC -2.60, adjusted p = 0.001) in the treated cell line with the highest connectivity score among cancer genes. Analysis of TCGA data revealed overexpression of <em>BUB1B</em> compared to normal in most cancers and overexpression was associated with poor prognosis. <em>BUB1B</em> also showed a highly significant positive correlation with <em>FOXM1</em> in all the TCGA cancer types. We used human leukemic cell lines (K562 and U937) as an <em>in vitro</em> study model to validate our findings. We found that NSP-B treatment of leukemic cells suppressed the expression of FOXM1 and BUB1B in a dose-dependent manner. In addition, NSP-B also resulted in the downregulation of FOXM1-regulated genes such as Aurora kinase A, Aurora kinase B, CDK4, and CDK6. Suppression of FOXM1 either by siRNA or NSP-B reduced BUB1B expression and enhanced cell survival inhibition and induction of apoptosis. Interestingly combination treatment of thiostrepton and NSP-B suppressed of cell viability and inducted apoptosis in leukemic cells <em>via</em> enhancing the activation of caspase-3 and caspase-8 compared with single-agent treatment. These results demonstrate the important role of the FOXM1/BUB1B pathway in leukemia and thus a potential therapeutic target. </p>
<h2>Other Information</h2>
<p>Published in: Frointiers in Oncolgy<br>
License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>
See article on publisher's website: <a href="http://dx.doi.org/10.3389/fonc.2022.929996" target="_blank">http://dx.doi.org/10.3389/fonc.2022.929996 </a></p>
Funding
Open Access funding provided by the Qatar National Library.